View Older Stories View More Recent Stories
-
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
-
Biogen (BIIB) and Eisai Receive Positive CHMP Opinion in the EU for Lecanemab in Early Alzheimer’s Disease
-
EMA says Leqembi recommended for treatment of early Alzheimer’s disease
-
Citi Starts Biogen (BIIB) at Neutral
-
Biogen (BIIB) PT Lowered to $275 at TD Cowen
-
Biogen (BIIB) PT Lowered to $255 at Oppenheimer
-
Biogen (BIIB) PT Lowered to $260 at RBC Capital
-
Morgan Stanley Downgrades Biogen (BIIB) to Equalweight
-
Biogen (BIIB) PT Raised to $315 at Piper Sandler
-
Goldman Sachs Reiterates Buy Rating on Biogen (BIIB)
-
Biogen (BIIB) Tops Q3 EPS by 31c; raises guidance
-
Stocks expected to have increasing option volume: BIIB FPN EAT MDLZ CMG EA FSLR SNAP CZR QRVO CAKE BAC FHN
-
Biogen (BIIB) Appoints Daniel Quirk, MD, as Chief Medical Officer
-
Truist Securities Reiterates Buy Rating on Biogen (BIIB)
-
Biogen (BIIB) Announces CFO Retirement
-
BMO Capital Reiterates Outperform Rating on Biogen (BIIB)
-
Biogen's (BIIB) Tecfidera Patent Upheld at European Patent Office - Bloomberg
-
Biogen (BIIB) Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024
-
Raymond James Resumes Biogen (BIIB) at Market Perform
-
Biogen (BIIB) Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients
-
Biogen (BIIB): New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA
-
RBC makes changes to its Top 30 Global Ideas for 2024
-
SAGE Therapeutics (SAGE) Announces Discontinuation of the Collaboration with Biogen on the SAGE-324 Program
-
BMO Capital Reiterates Outperform Rating on Biogen (BIIB)
-
Baird Reiterates Outperform Rating on Biogen (BIIB)
-
TD Cowen Reiterates Buy Rating on Biogen (BIIB)
-
Biogen (BIIB) and UCB Report Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus
-
Samsung Bioepis and Biogen (BIIB) Receive Positive CHMP Opinion for Aflibercept Biosimilar, OPUVIZ
-
Biogen (BIIB) Appoints Lloyd B. Minor and Mene Pangalos to its Board
-
BMO Capital Reiterates Outperform Rating on Biogen (BIIB)
-
Biogen (BIIB) Reports Positive Topline Results from Study of Higher Dose Regimen of Nusinersen
-
BMO Capital Reiterates Outperform Rating on Biogen (BIIB)
-
Biogen (BIIB) PT Lowered to $251 at Mizuho
-
Biogen (BIIB) PT Lowered to $302 at Truist Securities
-
Biogen (BIIB) PT Raised to $292 at RBC Capital
-
Midday movers: Meta Platforms, Lilly rise; Arm, Moderna fall
-
Biogen (BIIB) tops Q2 expectations, raises profit guidance
-
Biogen (BIIB) Tops Q2 EPS by 127c; profit guidance raised
-
Biogen (BIIB) Reports New Data Showing Three Years of Continuous Treatment with Dual-Acting LEQEMBI Continues to Significantly Benefit Early Alzheimer's Disease Patients
-
Biogen (BIIB), Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease
-
RBC's biotech survey shows investors more bearish vs. last time
-
Biogen (BIIB) PT Lowered to $294 at Baird
-
Eisai slumps 13% as EU regulators reject Alzheimer’s treatment developed with Biogen
-
Goldman Sachs Reiterates Buy Rating on Biogen (BIIB), 'We next await the August 1 earnings call'
-
Midday movers: Bristol-Myers, 3M and Deckers rise; Dexcom falls
-
Biogen (BIIB) PT Lowered to $307 at Piper Sandler
-
Biogen (BIIB) PT Lowered to $282 at RBC Capital
-
Biogen (BIIB): EMA has adopted a negative opinion on MAA of Lecanemab for early Alzheimer’s disease
-
SAGE Therapeutics (SAGE) Falls 24% After Phase 2 KINETIC 2 Study of SAGE-324 Fails
-
SAGE Therapeutics (SAGE) and Biogen (BIIB) Report Topline Results from Phase 2 KINETIC 2 Study of SAGE-324
